US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Nasdaq Biotechnology ETF

35.79

-0.0047-0.01%

Volume:9K

Turnover:307.59K

Market Cap:97.34M

PE:- -

High:36.45

Open:35.93

Low:35.75

Close:35.79

52wk High:36.84

52wk Low:23.42

Shares:2.72M

Float Shares:2.72M

Volume Ratio:0.65

T/O Rate:0.31%

Dividend:0.26

Dividend Rate:0.72%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens

THOMSON REUTERS

Moderna Inc. Stock Slips 4.6%, Underperforms Peers

Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

Healthcare Sector Set for Selective Gains in Second Half, Says Great Wall Fund Manager

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live

Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026

Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.

AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial

Amgen - Tezspire Safety Profile Consistent with Approved Indications

THOMSON REUTERS

Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints

THOMSON REUTERS

Innovative Drug Sector Resurgence: Fund Manager Breaks Down the Rally's Driving Forces

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/IBBQ/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":35.7853,"timestamp":1788365754414,"preClose":35.79,"halted":0,"volume":8515,"delay":0,"changeRate":-0.00013132159821178273,"floatShares":2720001,"shares":2720001,"eps":0,"marketStatus":"Trading","change":-0.0047,"latestTime":"09-02 12:17:05 EDT","open":35.93,"high":36.45,"low":35.7472,"amount":307591.96864499996,"amplitude":0.019637,"askPrice":35.87,"askSize":3200,"bidPrice":35.84,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":35.79,"sharesOutstanding":2520001,"nav":35.43802,"aum":96391449.83802,"dividendRate":0.007154,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":35.79,"preClose":35.79,"latestTime":"07:00 EDT","volume":100,"amount":3579.2799999999997,"timestamp":1788346812804,"change":0,"changeRate":0,"amplitude":0.007823},"postHourTrading":{"tag":"盘后","latestPrice":35.79,"preClose":35.79,"latestTime":"19:30 EDT","volume":10,"amount":357.9,"timestamp":1788305405837,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.646749,"impliedVol":0.2723,"impliedVolPercentile":0.8929},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2720001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.646749,"shares":2720001,"dividePrice":0.256,"high":36.45,"amplitude":0.019637,"preClose":35.79,"low":35.7472,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":35.7853,"committee":-0.828571,"eps":0,"divideRate":0.007154,"volume":8515,"delay":0,"ttmEps":0,"open":35.93,"prevYearClose":28.3962,"prevWeekClose":35.47,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":36.57,"twentyDayClose":32.93,"sixtyDayClose":28.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662036301","title":"US FDA Approves Gilead's Once-Daily Combination Pill for HIV Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036301","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036301?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867441,"startTime":"0","endTime":"0","summary":"US FDA approves Gilead's once-daily combination pill for HIV treatmentAug 27 -The U.S. Food and Drug Administration has approved Gilead Sciences'GILD.Oonce daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the company said on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O24M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","SG9999015945.SGD","LU0965509010.AUD","LU0114720955.EUR","LU2468319806.SGD","LU1934455277.USD","LU0889565916.HKD","BK4578","BK4588","LU0122379950.USD","IE00B19Z3581.USD","LU1023059063.AUD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0289739699.SGD","LU1934455863.HKD","BIB","IBBQ","LU0234570918.USD","LU1674673428.USD","LU2324357040.USD","MEDI","TBXU","LU1066051498.USD","LU1037948897.HKD","TMED","LU1061106388.HKD","LU1778281490.HKD","LU2357627491.SGD","BK4139","LU0861579265.USD","BBH","BK4585","LU1057294990.SGD","LU1585245621.USD","SG9999015952.SGD","GILD","BMED","BK4566","LU0882574055.USD","IE00B19Z3B42.SGD","IBB","LU0965508806.USD","LU1839511570.USD","BK4583","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0965509101.SGD","LU1037948541.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036807","title":"U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv, Including Those on Complex Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036807?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:47","pubTimestamp":1787867220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA7M9KZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015978.USD","LU2468319806.SGD","LU0965509010.AUD","LU1066051498.USD","BK4578","IE00B19Z3B42.SGD","BK4550","LU0289739699.SGD","IBB","IBBQ","BK4583","LU0320765992.SGD","BIB","LU1066053197.SGD","LU2089984988.USD","BK4588","MEDI","BK4566","BMED","IE00BZ1G4Q59.USD","BK4532","IE00B3T34201.USD","BBH","LU0882574055.USD","LU1934455194.USD","IE00BKVL7J92.USD","TMED","IE00B7SZLL34.SGD","TBXU","LU1934455863.HKD","LU1839511570.USD","GILD","LU1430594728.SGD","LU0889565916.HKD","LU0965509283.SGD","LU1571399168.USD","LU1057294990.SGD","LU1934455277.USD","LU1037948897.HKD","LU0234570918.USD","LU0823416689.USD","LU2087621335.USD","SG9999015945.SGD","LU1778281490.HKD","BK4568","BK4585","LU0109394709.USD","LU2112291526.USD","LU1061106388.HKD","LU0861579265.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033626","title":"Moderna Inc. Stock Slips 4.6%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033626?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:34","pubTimestamp":1787862840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. slid 4.6% to $142.77 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.6% to 26,541.35 and the Dow Jones Industrial Average rising 0.2% to 53,569.44.This was the stock's second consecutive day of losses.Moderna Inc. closed 19.2% short of its 52-week high of $176.66, which the company reached on August 19th.The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 1.6% to $265.77, Pfizer Inc. fell 1.0% to $28.02, and Gilead Sciences Inc. rose 0.52% to $148.86.Trading volume totaled 24.9 million, compared to the 50-day average of 16.4 million.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU1037948541.HKD","LU2324357040.USD","IDNA","LU0861579265.USD","SG9999015945.SGD","LU0058720904.USD","GNOM","IE00BKVL7J92.USD","BIB","BK4583","BK4550","LU2357627491.SGD","BK4568","BK4139","LU0114720955.EUR","LU1934455277.USD","LU1934455194.USD","TBXU","MEDI","LU2468319806.SGD","GILD","LU0109394709.USD","LU1674673691.USD","IE00B7SZLL34.SGD","LU1674673428.USD","LU0889565916.HKD","SG9999015952.SGD","BK4534","BK4588","LU0320765992.SGD","LU0965508806.USD","IBBQ","BK4551","LU1061106388.HKD","LU1066053197.SGD","MRNY","BBH","LU0965509010.AUD","MRNA","IE00B19Z3581.USD","BK4533","MRNX","BMED","SG9999015986.USD","LU0965509283.SGD","WDNA","LGHT","LU1571399168.USD","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084187","title":"Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084187","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084187?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:31","pubTimestamp":1787848308,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has started a new Phase 1 trial called “A Phase 1, Open-La...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBE","LU0058720904.USD","LU1571399168.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0109394709.USD","IBBQ","BK4533","LU0122379950.USD","BBC","LU2468319806.SGD","LU2112291526.USD","BK4588","LU0320765992.SGD","LU1057294990.SGD","IE0009355771.USD","BK4566","IE00B4R5TH58.HKD","AMGN","TBXU","BK4599","PJP","SG9999001440.SGD","BIB","LU0889565916.HKD","LU2089984988.USD","LU1061106388.HKD","LU2242652126.USD","IBB","BK4581","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4585","LU1983299246.USD","LU0289739699.SGD","LU0868494617.USD","LU1023059063.AUD","BBH","BK4534","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662813780","title":"Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662813780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662813780?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:20","pubTimestamp":1787844046,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verrica Pharmaceuticals (VRCA) and Amgen (AMGN). Verrica Pharmace...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBBQ","IE00BJT1NW94.SGD","LU1057294990.SGD","LU2468319806.SGD","LABU","AMGN","XLV","LU2089984988.USD","IBB","LU0109394709.USD","BIB","HCSG","BBH","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0122379950.USD","LU2112291526.USD","LU0058720904.USD","LU0868494617.USD","LU1571399168.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","BK4137","PBE","LU0029874061.USD","LU0128526141.USD","BK4581","BK4007","VRCA","TBXU","IE0009355771.USD","IE00B4R5TH58.HKD","BK4599","LU0889565916.HKD","BK4534","BK4139","XBI","LU2242652126.USD","BK4533","PJP","IE0002141913.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU1983299246.USD","LU0289739699.SGD","BK4585","SG9999001440.SGD","BK4566","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084083","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839287,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings posted revenue of US$122.49 million for the six months ended June 30, 2026, up 20.9","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL77D5HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","PJP","BBH","LU0868494617.USD","BK4139","LU1983299246.USD","LU2112291526.USD","BK4534","BK4588","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4533","LU2242652126.USD","02142","IE00BJJMRZ35.SGD","LU1061106388.HKD","IBB","LU1571399168.USD","LU2242646821.SGD","LU0058720904.USD","SG9999001440.SGD","PBE","BK1574","LU0889565916.HKD","LU1023059063.AUD","BK1583","LU2089984988.USD","IBBQ","TBXU","LU0122379950.USD","IE00BJT1NW94.SGD","BIB","IE0002141913.USD","BK4585","AMGN","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4566","LU2468319806.SGD","LU1057294990.SGD","LU0109394709.USD","BK4599","BK4581","BK1161","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195720547","title":"IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed","url":"https://stock-news.laohu8.com/highlight/detail?id=1195720547","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195720547?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:24","pubTimestamp":1787837055,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) has announced that the Phase II clinical trial evaluating IMM2510 (Peravrafusp alfa) in combination with IMM27M (Tazebsumab) as a first-line treatment for patients with advanced...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COAL","IBBQ","BK1161","IBBJ","MDTX","01541","BK4006","PSYK","HCC","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662013447","title":"Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements","url":"https://stock-news.laohu8.com/highlight/detail?id=2662013447","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662013447?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:15","pubTimestamp":1787829352,"startTime":"0","endTime":"0","summary":"Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","BBH","LU2242652126.USD","BK4588","LU0868494617.USD","LU2237443622.USD","LU0432979614.USD","BK4139","AMGN","IBBQ","LU1829250122.USD","BK4581","AZN","LU2468319806.SGD","BK4534","LU2417539215.USD","BK4007","IE00B3T34201.USD","LU2237443978.SGD","LU0128525929.USD","LU2242646821.SGD","BK4568","IE00B4R5TH58.HKD","LU1057294990.SGD","LU2237443382.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU2237443465.HKD","BIB","BK4533","TBXU","LU0122379950.USD","LU2462157665.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","PBE","PJP","LU0289739699.SGD","LU2456880835.USD","IE0009355771.USD","LU2236285917.USD","LU1023059063.AUD","AZNH","LU0708994859.HKD","LU1267930573.SGD","LU2089984988.USD","BK4566","BK4585","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101395901","title":"Healthcare Sector Set for Selective Gains in Second Half, Says Great Wall Fund Manager","url":"https://stock-news.laohu8.com/highlight/detail?id=1101395901","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101395901?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:41","pubTimestamp":1787827277,"startTime":"0","endTime":"0","summary":"After a period of correction and consolidation, the healthcare sector has shown robust performance over the past two months, with the once-prominent \"golden track\" seemingly returning to mainstream...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","09939","159992","06978","159938","MEDX","LNGR","BK1574","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191071495","title":"CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1191071495","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191071495?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826628,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its developed SYH2092 injection has received approval from China's National Medical Products Administration to proceed with clinical trials within the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","01093","LU0140636845.USD","LU0501845795.SGD","LU0067412154.USD","LU1226287875.USD","LU1328277881.USD","LU0314109678.HKD","LU1807302812.USD","IE00BZ08YS42.EUR","BK1521","IE00BZ08YT58.USD","LU0326950275.SGD","LU1226287529.USD","KURE","BK1515","IBBQ","MDTX","HK0000165453.HKD","LU1993786604.SGD","IE00B543WZ88.USD","LU1152091168.USD","LU0315179316.USD","IE0008368742.USD","IE0008369823.USD","LU1813983027.USD","SG9999004220.SGD","BK1191","LU1152091754.HKD","IE00B031HY20.USD","LU2039709279.SGD","PSYK","IE00B5MMRT66.SGD","LU1226288253.USD","IBBJ","LU1960683339.HKD","LU1951186391.HKD","LU1008478684.HKD","LU0880133367.SGD","LU1226287792.SGD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708043","title":"China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708043?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:08","pubTimestamp":1787825320,"startTime":"0","endTime":"0","summary":"China's JW Therapeutics interim revenue rises 4.7% on Carteyva salesOverviewChina cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva salesGross profit margin improved t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","LU0395794307.EUR","BBH","LU0463099449.HKD","IBB","IBBQ","IE0004445239.USD","LU1934455277.USD","LU2237443382.USD","LU2237443978.SGD","LU2097828714.EUR","XLV","MEDX","LU1037948897.HKD","RXL","IE00BVYPNV92.GBP","02126","LU0868494617.USD","LU1934455863.HKD","IE000SO60NU8.SGD","IYH","IE00BN8TJ469.HKD","REGN","TRUH","FHLC","PJP","LU0859254822.USD","FTXH","LU1188198961.HKD","LU0310799852.SGD","CMI","AGNG","PPH","TBXU","LU0949170772.SGD","BK1574","GLAM","LU0943347566.SGD","VHT","688331","KURE","LU2362541513.USD","LU0708994859.HKD","MADE","LU1244550577.SGD","03692","01801","IXJ","JDOC","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708397","title":"JW Cayman Therapeutics FY26 H1 IFRS Loss Narrows 81.14% to RMB 50.4 Million; Revenue Rises 4.7% to RMB 111.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708397","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708397?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:58","pubTimestamp":1787824692,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics FY26 H1 IFRS loss narrows 81.14% to RMB 50.4 million; revenue rises 4.7% to RMB 111.4 millionJW Cayman Therapeutics posted IFRS revenue of RMB 111.4 million, up 4.7% year over y","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8Yh1j4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126","LU0053666078.USD","BK1583","LU0058720904.USD","LU2362540622.SGD","BK4588","LU0823416689.USD","LU2106854487.HKD","LU0320765992.SGD","LU0289739699.SGD","REGN","BK4139","LU2362541513.USD","LU0109394709.USD","LU0114720955.EUR","LU0889565916.HKD","LU0823434583.USD","BBH","LU2237438978.USD","LU2089984988.USD","LU2468319806.SGD","LU0882574055.USD","LU1917777945.USD","BK4585","TBXU","IBBQ","LU0823434740.USD","LU2023250504.SGD","LU2362541273.HKD","IBB","LU1974910355.USD","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662877754","title":"Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662877754","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662877754?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:15","pubTimestamp":1787822113,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esop...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZN","BBH","LU0029864427.USD","LU1023059063.AUD","PJP","LU1983299246.USD","BK4599","IBB","LU1267930573.SGD","LU2456880835.USD","PBE","LU2237443465.HKD","BK4533","LU0128525929.USD","BK4585","AMGN","LU1829250122.USD","BIB","LU0889565916.HKD","IE00BJT1NW94.SGD","LU2417539215.USD","LU1061106388.HKD","TBXU","IE0002141913.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00B3T34201.USD","LU2236285917.USD","LU2237443895.HKD","LU2237443978.SGD","BK4588","BK4568","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU2112291526.USD","LU2242646821.SGD","IBBQ","BK4007","LU0122379950.USD","AZNH","LU0289739699.SGD","BK4581","LU0432979614.USD","LU0058720904.USD","IE00B2B36J28.USD","LU2468319806.SGD","IE0009355771.USD","LU1571399168.USD","LU0868494617.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771175","title":"AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771175","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771175?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:24","pubTimestamp":1787819085,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Amgen  said Thursday their drug Tezspire met the primary endpoints of a Phase 3 trial treating eosinophilic esophagitis, a chronic inflammatory esophagus disorder.The medication met both primary endpoints by reducing tissue inflammation and easing swallowing difficulties at week 24 compared to a placebo, the companies said.The disease and symptom improvements were maintained through week 52 for both tested doses, they said.The companies also said the safety profile of the treatment during the study remained consistent with its previously approved uses.Shares of Amgen were down by over 1% in Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TBXU","AZNH","IE00B4R5TH58.HKD","BK4534","LU2462157665.USD","LU2237443622.USD","LU2242652126.USD","LU0058720904.USD","LU0889565916.HKD","BBH","LU2242646821.SGD","BK4533","PJP","LU0708994859.HKD","BK4585","LU2089984988.USD","LU2237443465.HKD","LU1057294990.SGD","LU1061106388.HKD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","LU0128525929.USD","LU1267930573.SGD","BK4566","IE00BJT1NW94.SGD","LU2456880835.USD","IE00BFTCPJ56.SGD","LU0432979614.USD","LU1829250122.USD","BK4599","LU0029864427.USD","LU0310800379.SGD","AMGN","BIB","BK4581","IBBQ","AZN","IBB","LU0109394709.USD","LU2237443382.USD","LU0868494617.USD","LU1571399168.USD","IE00B2B36J28.USD","PBE","BK4007","LU2237443549.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775710","title":"Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775710?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:55","pubTimestamp":1787813720,"startTime":"0","endTime":"0","summary":"The latest update is out from Vertex Corp. ( ($JP:5290) ). Vertex Corporation has been selected as a constituent of the JPX-Nikkei Mid and Small Ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-corp-added-to-jpx-nikkei-mid-and-small-cap-index-for-fy2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-corp-added-to-jpx-nikkei-mid-and-small-cap-index-for-fy2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRTX","IE00B2B36J28.USD","LU2468319806.SGD","IE00BZ9MQY76.HKD","LU2462157665.USD","VERX","BK4567","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","IBB","IBBQ","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4533","LU1585245621.USD","PBE","BIB","IE0002141913.USD","IE00B19Z3581.USD","LU2089984988.USD","IE00B19Z9P08.USD","IE00BJT1NW94.SGD","LU1069344957.HKD","LU1559883803.SGD","LU1815336091.USD","LU0566484027.USD","JPX","BK4532","BBH","SG9999013999.USD","LU0432979614.USD","TBXU","IE0002270589.USD","LU1093756168.USD","LU1430594728.SGD","BK4023","LU0079474960.USD","SG9999001176.USD","LU2417539215.USD","SGXZ57979304.SGD","LU2456880835.USD","LU0234570918.USD","LU0823416689.USD","LU1778281490.HKD","BK4585","IDNA","LU0109394709.USD","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662477574","title":"Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662477574","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662477574?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:55","pubTimestamp":1787813711,"startTime":"0","endTime":"0","summary":"The latest update is out from Vertex Corp. ( ($JP:5290) ). Vertex Corporation has updated its earlier disclosures on changes to directors and offic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-corp-refines-leadership-structure-at-key-subsidiary-vertex-co?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-corp-refines-leadership-structure-at-key-subsidiary-vertex-co?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","LU1815336091.USD","LU0320765992.SGD","SG9999001176.USD","TBXU","VRTX","BK4532","LU0058720904.USD","LU2362541273.HKD","BBH","LU2462157665.USD","GNMX","LU0234570918.USD","BK4139","LU1035775433.USD","BIB","LU1559883803.SGD","IE00B19Z9P08.USD","BK4585","LU2362541513.USD","LU0566484027.USD","IE00BZ9MQY76.HKD","BK4567","LU1674673428.USD","LU0109394709.USD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","LU0417517546.SGD","LU0256863811.USD","IBBQ","LU0889565916.HKD","IE00BJT1NW94.SGD","BK4533","LU1430594728.SGD","LU2417539215.USD","SGXZ57979304.SGD","IE0002270589.USD","IBB","LU0061475181.USD","LU0289739699.SGD","LU0757428866.USD","VERX","LU0823416689.USD","LU2456880835.USD","LU1093756325.SGD","IDNA","IE00B19Z3581.USD","LU0079474960.USD","LU2236285917.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662514775","title":"AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662514775","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662514775?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:40","pubTimestamp":1787812818,"startTime":"0","endTime":"0","summary":"UPDATE 3-AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trialAug 27 (Reuters)-AstraZenecaAZN.Lsaid on Thursday its asthma drug Tezspire met the main goals of a late-stage tria","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1051770623.HKD","IBB","03165","LU1481600234.SGD","BIB","LU0997586432.USD","LU1153584641.USD","LU1571399168.USD","LU0345777659.USD","LU0997586515.USD","LU1119994496.HKD","LU1880407132.USD","LU1003077747.HKD","IE00BFTCPJ56.SGD","LU0052756011.USD","LU0738911758.USD","LU1267930490.SGD","LU2237443382.USD","AZN.UK","LU0661504455.SGD","LU0823434583.USD","LU1170363599.USD","LU1829250122.USD","LU0432979614.USD","LU2293690082.USD","LU0575583348.USD","LU0047473722.EUR","PBE","LU2242652126.USD","BBH","LU0792757196.USD","BK4588","BK4599","TBXU","LU0887340254.USD","LU1974910355.USD","LU0077335932.USD","LU1057294990.SGD","LU0266013472.USD","LU0122379950.USD","PJP","LU0310799852.SGD","AMGN","SGXZ57979304.SGD","LU0640478417.SGD","LU2237443622.USD","LU3187612489.SGD","REGN","IBBQ","LU0972486137.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778025","title":"Amgen - Tezspire Safety Profile Consistent with Approved Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778025?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:00","pubTimestamp":1787810401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA3XV48Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBBQ","LU1023059063.AUD","LU0868494617.USD","BBH","BK4599","LU2242646821.SGD","BK4585","BIB","IE00BJJMRZ35.SGD","LU2112291526.USD","LU0109394709.USD","LU2468319806.SGD","IE0002141913.USD","BK4588","AMGN","LU2242652126.USD","LU0889565916.HKD","LU1057294990.SGD","IE0009355771.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4533","LU1571399168.USD","PBE","BK4581","BK4534","LU0320765992.SGD","IE00BFTCPJ56.SGD","PJP","SG9999001440.SGD","IE00BJT1NW94.SGD","LU1983299246.USD","IBB","LU0122379950.USD","BK4566","LU2089984988.USD","LU0289739699.SGD","LU0058720904.USD","TBXU","LU1061106388.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662728778","title":"Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662728778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662728778?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:00","pubTimestamp":1787810401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA3XV48Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","PJP","BBH","LU0868494617.USD","BK4139","LU1983299246.USD","LU2112291526.USD","BK4534","BK4588","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4533","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","IBB","LU1571399168.USD","LU2242646821.SGD","LU0058720904.USD","SG9999001440.SGD","PBE","LU0889565916.HKD","LU1023059063.AUD","LU2089984988.USD","IBBQ","TBXU","LU0122379950.USD","IE00BJT1NW94.SGD","BIB","IE0002141913.USD","BK4585","AMGN","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4566","LU2468319806.SGD","LU1057294990.SGD","LU0109394709.USD","BK4599","BK4581","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153198003","title":"Innovative Drug Sector Resurgence: Fund Manager Breaks Down the Rally's Driving Forces","url":"https://stock-news.laohu8.com/highlight/detail?id=1153198003","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153198003?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:30","pubTimestamp":1787801432,"startTime":"0","endTime":"0","summary":"As interim earnings reports flood the market, the innovative drug sector has reignited investor enthusiasm, with several leading stocks surging post-results. On August 26, Innovent Biologics jumped...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","MEDX","BK1574","IBBQ","159992","520880","LNGR","06978","FLHK","159316"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}